Nation’s first approved personalized cellular therapy now available for second indication
Novartis is blazing ahead with its bid to take its new CAR-T therapy, Kymriah, into new realms with a double-pronged approval application in Europe.
your submission has already been received.
Please enter a valid Email address！
The most relevant industry news & insight will be sent to you every two weeks.
Copyright © 2016-2018 Drugdu.com. All Rights Reserved.